Pomotrelvir: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -1% 1 230 Improvement, Studies, Patients Relative Risk Viral clearance -39% 1 123 RCTs -1% 1 230 Early -1% 1 230 Pomotrelvir for COVID-19 c19early.org December 2025 Favorspomotrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -1% 1.01 [0.50-2.04] no recov. 20/153 10/77 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk All studies -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk 1 pomotrelvir COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Effect extraction pre-specified(most serious outcome) Favors pomotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -1% 1.01 [0.50-2.04] no recov. 20/153 10/77 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk All studies -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk 1 pomotrelvir COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Favors pomotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -39% 1.39 [0.15-13.0] viral+ 3/84 1/39 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.78 Early treatment -39% 1.39 [0.15-13.0] 3/84 1/39 39% higher risk All studies -39% 1.39 [0.15-13.0] 3/84 1/39 39% higher risk 1 pomotrelvir COVID-19 viral clearance result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.78 Favors pomotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -1% 1.01 [0.50-2.04] no recov. 20/153 10/77 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk All studies -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk 1 pomotrelvir COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Effect extraction pre-specified(most serious outcome) Favors pomotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -1% 1.01 [0.50-2.04] no recov. 20/153 10/77 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk All studies -1% 1.01 [0.50-2.04] 20/153 10/77 1% higher risk 1 pomotrelvir COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Effect extraction pre-specified(most serious outcome) Favors pomotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Borroto-.. (DB RCT) -1% 1.01 [0.50-2.04] no recov. 20/153 10/77 Improvement, RR [CI] Treatment Control Borroto-.. (DB RCT) -6% 1.06 [0.52-2.13] no recov. 21/153 10/77 Borroto-.. (DB RCT) 4% 0.96 [0.49-1.89] no recov. 21/153 11/77 Borroto-.. (DB RCT) -252% 3.52 [0.82-15.1] misc. 14/153 2/77 Borroto-.. (DB RCT) -39% 1.39 [0.15-13.0] viral+ 3/84 1/39 Borroto-.. (DB RCT) -15% 1.15 [0.79-1.67] viral+ 47/84 19/39 Pomotrelvir COVID-19 outcomes c19early.org December 2025 Favors pomotrelvir Favors control